Herbal Monograph
Pygeum
Prunus africana (Hook.f.) Kalkman
Rosaceae
Clinically proven African bark extract for prostate health and urinary symptom relief in BPH
Overview
Plant Description
Prunus africana is a large, evergreen hardwood tree growing 10-25 m (33-82 ft) in height, occasionally reaching up to 40 m (130 ft) in favorable conditions. The trunk is straight and cylindrical, up to 1 m in diameter, covered in dark brown to blackish-brown bark that is rough, fissured, and scaly, exuding a characteristic reddish-brown coloration when freshly cut -- giving rise to the common name 'Red Stinkwood.' The inner bark has a distinctive bitter, almond-like smell when freshly stripped. Leaves are alternate, simple, elliptic to oblong-lanceolate, 5-13 cm long, with serrated margins, glossy dark green above and lighter beneath, resembling cherry leaves. The leaf petiole is often pinkish-red. Flowers are small, white to greenish-white, fragrant, arranged in racemose clusters 5-8 cm long in the leaf axils. Individual flowers are actinomorphic with 5 petals and numerous stamens, typical of Rosaceae. The fruit is a small drupe, approximately 7-13 mm in diameter, globose, dark reddish-brown to purplish-black when ripe, with thin flesh surrounding a single hard seed. The tree is dioecious (some populations) or monoecious and is pollinated primarily by insects. It is a slow-growing, long-lived tree that may take 15-25 years to reach harvestable bark maturity.
Habitat
Prunus africana is a montane forest species, occurring primarily in Afromontane forests at elevations between 900 and 3,400 m (2,950-11,150 ft), with optimal growth between 1,500 and 2,500 m. It thrives in moist, humid mountain environments with well-drained, deep soils rich in organic matter. The tree prefers moderate to high rainfall (1,000-2,500 mm/year) and is often found along forest margins, in gallery forests, and in disturbed montane habitats. It occurs as a canopy or sub-canopy tree in mixed Afromontane forests, frequently associated with species such as Podocarpus, Juniperus, Olea, and other Prunus relatives. The species is shade-tolerant in its juvenile phase but requires canopy gaps for full maturation and fruiting.
Distribution
Prunus africana has a wide but discontinuous distribution across sub-Saharan Africa and several island populations. It occurs in the montane forests of approximately 22 African countries, with major populations in: Cameroon (Mount Cameroon, Bamenda Highlands -- historically the largest commercial source), Madagascar (eastern montane forests -- significant exploitation), Democratic Republic of Congo (eastern highlands), Kenya (Mount Kenya, Aberdare Range, Mau Forest), Tanzania (Mount Kilimanjaro, Usambara Mountains), Ethiopia (southwestern highlands), Uganda (Mount Elgon, Rwenzori Mountains), Equatorial Guinea (Bioko Island), and South Africa (along the Drakensberg escarpment, Mpumalanga, Limpopo, and KwaZulu-Natal). Disjunct island populations also occur on Bioko, Sao Tome, Grande Comore, and the Canary Islands. This wide distribution across African montane 'sky islands' has resulted in significant genetic variation among populations. The species is listed on CITES Appendix II due to over-exploitation for bark harvesting, and wild populations in several countries (notably Cameroon and Madagascar) have declined significantly.
Parts Used
Stem bark (Pygei africani cortex)
Preferred: Standardized lipophilic extract (chloroform/methanol or n-hexane extraction, standardized to contain 14% triterpenes and 0.5% n-docosanol); dried bark powder for capsules
The dried bark of the trunk and larger branches is the official drug. The bark contains the full spectrum of therapeutic constituents: phytosterols (beta-sitosterol and related sterols), pentacyclic triterpenes (ursolic acid, oleanolic acid), ferulic acid esters of long-chain fatty alcohols (especially n-docosanol), and tannins. The bark is the source material for the standardized lipophilic extract (Tadenan/V1326) used in the majority of clinical trials. Fresh bark has a strong, characteristic bitter-almond odor due to benzaldehyde and traces of cyanogenic glycosides. The dried bark is dark reddish-brown to almost black, hard, and fibrous. It is traditionally used in decoction in African medicine but is used almost exclusively as a standardized extract in Western phytotherapy and clinical practice.
Key Constituents
Phytosterols
Phytosterols, particularly beta-sitosterol, are considered primary active constituents responsible for the anti-inflammatory and anti-proliferative effects of Pygeum bark extract in the prostate. Beta-sitosterol competitively inhibits prostatic 5-alpha-reductase (reducing dihydrotestosterone formation), inhibits prostaglandin biosynthesis (especially PGE2) in prostatic tissue by blocking phospholipase A2 and cyclooxygenase-2, and modulates growth factor signaling in prostatic stromal and epithelial cells. A meta-analysis of beta-sitosterol preparations for BPH (Wilt et al. 1999, Cochrane) confirmed significant improvement in urinary symptom scores and flow measures. The phytosterol fraction is the primary basis for the standardization of commercial Pygeum extracts.
Pentacyclic triterpenes
Pentacyclic triterpenes are the second major class of active constituents in Pygeum bark, responsible for significant anti-inflammatory and anti-edema activity in prostatic tissue. The triterpene fraction inhibits the enzymatic pathways (5-lipoxygenase, cyclooxygenase-2, phospholipase A2) that generate pro-inflammatory and edema-promoting prostaglandins and leukotrienes in the prostate. Reduction of prostatic edema is considered a key mechanism by which Pygeum extract relieves urinary obstruction symptoms in BPH, as prostatic edema contributes to urethral compression independent of glandular hyperplasia. The standardized extract Tadenan/V1326 is normalized to contain approximately 14% total triterpenes (calculated as ursolic acid + oleanolic acid).
Ferulic acid esters of long-chain fatty alcohols (n-docosanol esters)
The ferulic acid esters of long-chain fatty alcohols represent a pharmacologically distinctive constituent class of Pygeum bark. The n-docosyl ferulate fraction specifically targets prostatic hormone metabolism: it inhibits 5-alpha-reductase (reducing conversion of testosterone to the more potent dihydrotestosterone in prostatic tissue), inhibits aromatase (reducing local estrogen production that promotes stromal proliferation), and inhibits basic fibroblast growth factor (bFGF)-induced proliferation of prostatic fibroblasts. This anti-proliferative activity on prostatic stroma is mechanistically distinct from the anti-inflammatory effects of the phytosterol and triterpene fractions, providing complementary therapeutic activity. The standardized extract is normalized to 0.5% n-docosanol (as docosyl ferulate) precisely because this fraction is considered pharmacologically essential.
Tannins and phenolic compounds
The tannin and phenolic fraction contributes to the traditional use of Pygeum bark decoctions in African medicine, where the astringent, tissue-toning, and anti-inflammatory properties of condensed tannins are relevant. In standardized lipophilic extracts (Tadenan), tannins are largely absent, and the therapeutic activity is attributed to phytosterols, triterpenes, and ferulic acid esters. The free ferulic acid contributes antioxidant protection.
Other lipophilic constituents
Minor lipophilic constituents that contribute to the overall extract matrix but are not considered primary active compounds for the therapeutic indications of Pygeum. The fatty acid fraction may enhance absorption of phytosterols and triterpenes.
Herbal Actions
Reduces inflammation
The primary pharmacological action of Pygeum bark extract relevant to its clinical use in BPH. The anti-inflammatory activity is prostate-specific in its clinical application, targeting the chronic non-bacterial inflammation (category IIIB prostatitis / inflammatory component of BPH) that contributes to prostatic enlargement and urinary symptoms. Mechanisms: beta-sitosterol inhibits prostaglandin biosynthesis (PGE2, PGF2-alpha) in prostatic tissue by blocking phospholipase A2 and COX-2; pentacyclic triterpenes (ursolic acid, oleanolic acid) inhibit 5-lipoxygenase and NF-kB inflammatory signaling; overall reduction of inflammatory mediators in the prostatic stroma reduces edema and congestion. The Cochrane systematic review (Ishani et al. 2000) and multiple RCTs confirmed symptomatic improvement consistent with anti-inflammatory and anti-edema mechanisms.
[1, 4, 5, 9]Increases urine production and output
Mild diuretic activity that contributes to the improvement of urinary symptoms in BPH. The mechanism is likely indirect -- reduction of prostatic edema and inflammation decreases urethral compression, improving urinary flow rate and reducing post-void residual volume. Some evidence suggests triterpenes (oleanolic acid) may have mild direct diuretic properties. Clinical trials consistently demonstrate increased maximum urinary flow rate (Qmax) and decreased post-void residual urine volume with Pygeum extract, though these effects are attributed to combined anti-edema and smooth muscle effects rather than a classical renal diuretic mechanism.
[4, 5, 6]Tightens and tones tissue, reduces secretions
Astringent action attributable to the condensed tannin (proanthocyanidin) content of the bark, more evident in traditional bark decoctions than in standardized lipophilic extracts. The tannins tone and tighten mucous membranes and tissues, reducing excessive secretions. This astringent quality is relevant to the traditional African use of the bark decoction for diarrhea, urinary tract complaints, and as a general tonic. The astringent-bitter profile also reflects the traditional energetic assessment of the bark.
[2, 3]Prevents or slows oxidative damage to cells
Antioxidant activity demonstrated for both the phytosterol and phenolic fractions of Pygeum bark extract. Beta-sitosterol and ferulic acid (free and esterified) scavenge reactive oxygen species and inhibit lipid peroxidation. Proanthocyanidins in crude bark preparations are potent antioxidants. Oxidative stress is implicated in the pathogenesis of BPH and chronic prostatitis, and the antioxidant activity of Pygeum may contribute to its clinical efficacy by protecting prostatic tissue from inflammatory oxidative damage.
[1, 9]Gradually restores proper body function and increases overall health
In the context of Western herbalism, Pygeum bark may be considered a mild alterative for the male genitourinary system, gradually improving tissue function and reducing pathological changes in the prostate over weeks to months of use. The combination of anti-inflammatory, anti-proliferative, and hormonal-modulating effects produces a gradual normalization of prostatic tissue rather than acute symptomatic relief. This is consistent with the clinical observation that optimal benefits from Pygeum extract are achieved after 6-8 weeks of continuous use.
[1, 4]Therapeutic Indications
Reproductive System
Benign prostatic hyperplasia (BPH) -- symptomatic relief
The primary and best-evidenced indication for Pygeum bark extract. The 2002 Cochrane systematic review by Ishani et al. analyzed 18 randomized controlled trials involving 1,562 men with BPH and found that Pygeum extract provided statistically significant improvement in overall urological symptoms (combined symptom score improved by 35% relative to placebo), maximum urinary flow rate (Qmax increased by 23%), and reduction of residual urine volume (decreased by 24%). Men taking Pygeum were more than twice as likely to report overall improvement in symptoms. The standardized extract Tadenan (100 mg/day) was the preparation used in the majority of trials. The French regulatory authority (AFSSAPS, now ANSM) approved Pygeum bark extract (Tadenan) for the treatment of functional symptoms of benign prostatic hyperplasia. Commission E-equivalent approvals exist in several European countries. WHO and ESCOP monographs support this indication.
[1, 4, 5, 6, 8, 13, 14]Lower urinary tract symptoms (LUTS) associated with BPH
LUTS encompass obstructive symptoms (hesitancy, weak stream, incomplete emptying, terminal dribbling) and irritative symptoms (frequency, urgency, nocturia) caused by prostatic enlargement and associated inflammation/edema. Pygeum extract addresses LUTS through multiple mechanisms: anti-inflammatory reduction of prostatic edema (reducing urethral compression), inhibition of prostatic growth factors (slowing glandular and stromal hyperplasia), and possible mild effect on detrusor muscle contractility. Nocturia in particular was significantly reduced in multiple RCTs -- Breza et al. (1998) reported a 32% reduction in nocturia frequency. The International Prostate Symptom Score (IPSS) consistently improved with Pygeum treatment across trials.
[4, 5, 6, 7]Chronic non-bacterial prostatitis (CP/CPPS, category III prostatitis)
The anti-inflammatory mechanisms of Pygeum bark extract are relevant to chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS), where persistent prostatic inflammation without bacterial infection produces pain, urinary symptoms, and reduced quality of life. Several clinical studies have shown improvement in prostatitis symptom scores with Pygeum extract, both as monotherapy and in combination with other agents (notably nettle root and saw palmetto). The prostatic anti-inflammatory action targeting PGE2 and leukotriene synthesis is mechanistically appropriate for this condition.
[1, 4, 9]Male sexual and reproductive health support (adjunctive)
In several African healing traditions, Pygeum bark is used to support male sexual function and fertility. Preliminary evidence suggests that Pygeum extract may improve seminal fluid composition -- specifically increasing prostatic secretion volume and improving the biochemical composition of seminal fluid (increased alkaline phosphatase and prostatic acid phosphatase activity). Luciani et al. (1984) reported improvements in seminal fluid quality parameters. This traditional indication aligns with the herb's overall affinity for male reproductive organ health, though clinical evidence specific to fertility outcomes is limited.
[1, 2]Urinary System
Nocturia (nighttime urinary frequency)
One of the most consistently demonstrated clinical effects of Pygeum extract across multiple RCTs. Nocturia is a particularly bothersome LUTS symptom that significantly impairs quality of life and sleep. The Cochrane review reported significant reduction in nocturia episodes with Pygeum treatment. Breza et al. (1998) specifically demonstrated a 32% reduction in nocturia frequency with Pygeum extract 50 mg twice daily. Barlet et al. (1990) also documented significant nocturia improvement. Mechanism involves reduced prostatic edema and congestion, improving bladder capacity and reducing nocturnal detrusor instability.
[4, 5, 6]Post-void residual urine volume reduction
Multiple RCTs included in the Cochrane review demonstrated a significant 24% reduction in post-void residual urine volume with Pygeum extract compared to placebo. Reduction of residual urine is clinically important as high residual volumes increase risk of urinary tract infection and indicate significant bladder outlet obstruction. The improvement is attributed to reduced urethral compression from decreased prostatic edema.
[4, 5, 7]Urinary flow improvement (increased maximum flow rate)
The Cochrane systematic review reported a mean improvement in maximum urinary flow rate (Qmax) of 23% relative to placebo. While the absolute improvement (approximately 2 mL/s) is modest, it reflects meaningful clinical improvement in an objective, measurable parameter. Improved flow rate correlates with reduced urethral obstruction from decreased prostatic edema and inflammation. Yablonsky et al. (1997) and Barlet et al. (1990) both demonstrated significant Qmax improvements.
[4, 6, 7]Endocrine System
Modulation of prostatic hormone metabolism (5-alpha-reductase inhibition)
The ferulic acid esters (n-docosyl ferulate) and phytosterols (beta-sitosterol) in Pygeum bark extract inhibit 5-alpha-reductase activity in prostatic tissue, reducing local conversion of testosterone to dihydrotestosterone (DHT). DHT is the primary androgen driving prostatic cell proliferation in BPH. Additionally, docosyl ferulate inhibits aromatase, reducing local estrogen production that promotes prostatic stromal growth. This dual hormonal modulation (anti-androgenic + anti-estrogenic) at the prostatic tissue level is mechanistically distinct from systemic hormonal drugs (finasteride, dutasteride) and operates without significant systemic endocrine side effects at recommended doses.
[1, 4, 9]Musculoskeletal System
Inflammation and pain associated with musculoskeletal conditions (traditional use)
In sub-Saharan African traditional medicine, P. africana bark decoctions are used for a broader range of inflammatory conditions beyond the prostate, including fever, joint inflammation, and generalized pain. The anti-inflammatory triterpenes (ursolic acid, oleanolic acid) have demonstrated activity in preclinical models of inflammation beyond the prostate. However, clinical evidence for musculoskeletal indications is absent, and modern clinical use is focused almost exclusively on prostate and urinary conditions.
[2, 3]Energetics
Temperature
neutral
Moisture
slightly dry
Taste
Tissue States
damp/stagnation, hot/excitation
In Western herbal energetics, Pygeum bark is assessed as neutral in temperature (neither significantly warming nor cooling) and slightly drying in moisture quality, consistent with its astringent tannin content and tissue-toning action. The bitter taste reflects the alkaloid traces, terpenes, and phenolic compounds; the astringent taste reflects the condensed tannin content. Together, the bitter-astringent profile indicates an herb that tones lax, boggy tissue, reduces congestion and edema, and clears metabolic stagnation -- precisely the tissue-state picture seen in benign prostatic hyperplasia (congested, edematous, damp/stagnant prostate tissue with chronic low-grade inflammation or hot/excitation). Pygeum's energetics make it particularly suited to the damp/stagnation pattern in the male pelvic organs, where tissue has become boggy, swollen, and poorly draining. The neutral temperature means it is appropriate for both constitutionally warm and constitutionally cool individuals. CAVEAT: Herbal energetics are interpretive frameworks within Western herbalism, not standardized across all practitioners.
Traditional Uses
Sub-Saharan African traditional medicine (Cameroon, Central Africa)
- Bark decoction for 'old man's disease' -- a traditional diagnosis corresponding to difficult urination and prostatic symptoms in elderly men
- Treatment of urinary disorders including painful urination, frequent urination, and urinary incontinence
- General male reproductive and sexual health tonic
- Fever reduction and treatment of malaria-associated symptoms
- Stomach ache and gastrointestinal complaints
- Chest pain and respiratory conditions
- Wound healing when applied as a bark poultice
"Among the Bamileke, Bafut, and other peoples of the Cameroon highlands, P. africana bark is traditionally prepared as a decoction for treating 'mfueh' or related terms designating difficult urination in older men. The bark is boiled in water and the resulting bitter liquid is drunk daily. Traditional healers distinguish between the fresh bark (considered more potent) and dried bark. The bitter, astringent taste is recognized as a sign of the medicine's strength."
East African traditional medicine (Kenya, Kikuyu people)
- Known as 'Muiri' or 'Kirah' -- bark decoction used for urinary tract complaints
- Treatment of gonorrhea and other urogenital infections
- General tonic for male health and vitality in aging men
- Remedy for stomach pain and as a bitter digestive tonic
- Treatment of fever and inflammation
- The bark smoke is inhaled for chest congestion and respiratory conditions
"The Kikuyu people of the Kenya highlands use Muiri bark decoction as a traditional remedy for urinary complaints and as a tonic for aging men. The bark is harvested from mature trees on Mount Kenya and the Aberdare Range. Traditionally, the bark is stripped in small quantities and boiled immediately, as the fresh bark is considered more medicinally potent than dried material."
Southern African traditional medicine (South Africa, Zulu and other peoples)
- Known as 'Inyazangoma-elimnyama' or 'Red Stinkwood' -- bark used for abdominal pain and intestinal complaints
- Treatment of kidney and bladder disorders
- Bark decoction as a general tonic and blood purifier
- Applied topically for skin conditions and wounds
"In southern African traditional medicine, Prunus africana bark is known by various names across ethnic groups. The Zulu people use the bark decoction for internal complaints including stomach pain and urinary disorders. The reddish bark and its characteristic smell when freshly cut are recognized identification features among traditional healers."
French phytotherapy (since 1960s)
- Standardized lipophilic bark extract (Tadenan, V1326) for symptomatic treatment of benign prostatic hyperplasia
- Reduction of urinary frequency, nocturia, and improvement of urinary flow
- First-line or adjunctive phytotherapy for mild-to-moderate lower urinary tract symptoms
- Often combined with Serenoa repens (saw palmetto) or Urtica dioica (nettle root) for enhanced prostate support
"The French pharmaceutical company Laboratoires Fournier (later acquired by Solvay, then Abbott, now Mylan) developed the first standardized Pygeum bark extract (Tadenan) in 1969, based on ethnopharmacological leads from traditional Cameroonian medicine. Tadenan became one of the most prescribed phytomedicines for BPH in France and several other European countries. The French regulatory agency (Agence du Medicament, now ANSM) granted marketing authorization for Tadenan as a treatment for functional symptoms of benign prostatic hypertrophy."
Modern Research
Cochrane systematic review: Pygeum africanum for benign prostatic hyperplasia
The landmark Cochrane systematic review by Ishani et al. (2000) evaluated the efficacy and tolerability of Pygeum africanum bark extract for the treatment of BPH symptoms. This remains the most authoritative synthesis of clinical evidence for Pygeum and is the most widely cited reference in regulatory and clinical guidance documents.
Findings: Analyzed 18 randomized controlled trials involving 1,562 men with BPH. Pygeum extract (at doses of 75-200 mg/day, most commonly 100 mg/day of standardized extract) was significantly more effective than placebo across all primary outcome measures: (1) Overall symptom improvement: men on Pygeum were more than twice as likely to report global improvement (RR 2.1, 95% CI 1.4-3.1); (2) IPSS/AUA symptom score: 35% improvement relative to placebo; (3) Maximum urinary flow rate (Qmax): 23% improvement relative to placebo; (4) Post-void residual volume: 24% reduction relative to placebo; (5) Nocturia: significantly reduced across multiple trials. Tolerability was excellent, with adverse effects comparable to placebo in most trials. Gastrointestinal complaints were the most commonly reported adverse effect (~2% incidence).
Limitations: Several methodological limitations noted: (1) many included trials were short duration (4-12 weeks); (2) most trials used outdated non-validated symptom assessment instruments rather than the now-standard IPSS; (3) many trials were of moderate methodological quality (Jadad scores 2-3); (4) almost all trials used a single commercial product (Tadenan); (5) direct comparative data with pharmaceutical BPH treatments (alpha-blockers, 5-alpha-reductase inhibitors) were limited; (6) long-term outcomes (years) and disease progression data were not available.
[4]
Breza et al. RCT: Efficacy and tolerability of Pygeum extract in BPH
A multicenter, randomized, double-blind, placebo-controlled trial evaluating the clinical efficacy and safety of Pygeum africanum bark extract (Tadenan, 50 mg twice daily) in 263 men with symptomatic BPH over 60 days.
Findings: Pygeum extract produced statistically significant improvements in all primary endpoints compared to placebo: IPSS decreased by 40% (vs 20% for placebo, P < 0.001), maximum urinary flow rate increased significantly, nocturia episodes decreased by 32%, and post-void residual volume was significantly reduced. Quality of life scores improved substantially. The treatment was well-tolerated: adverse effects were reported by 4.8% of the Pygeum group vs 4.4% of placebo, with GI symptoms (nausea, stomach discomfort) being the most common. No serious adverse events occurred.
Limitations: 60-day treatment duration does not address long-term efficacy or disease progression. Single commercial extract product (Tadenan). Predominantly European population. Symptom assessment used the then-standard IPSS but did not include voiding diary or pressure-flow studies.
[5]
Barlet et al. comparative RCT: Pygeum versus Permixon (saw palmetto) for BPH
A multicenter, randomized, double-blind trial directly comparing Pygeum africanum extract (Tadenan, 100 mg/day) with Serenoa repens extract (Permixon/saw palmetto, 320 mg/day) in 1,098 men with moderate BPH symptoms over 60 days.
Findings: Both Pygeum and saw palmetto extracts produced clinically and statistically significant improvements in BPH symptoms compared to baseline. IPSS scores improved by approximately 35-40% in both groups. Maximum urinary flow rate improved similarly in both arms. Nocturia was significantly reduced in both groups. There was no statistically significant difference in efficacy between the two herbal extracts, suggesting comparable clinical effectiveness. Both treatments were well tolerated with low adverse event rates. This study was important for establishing Pygeum as comparable in efficacy to the better-known saw palmetto extract.
Limitations: No placebo arm in this study (active comparator design only). 60-day duration. Symptom assessment methodology varied. Both products were manufactured by the same parent company (Laboratoires Fournier for Tadenan; Pierre Fabre for Permixon). Does not address combination therapy.
[6]
Yablonsky et al. dose-finding RCT: once-daily versus twice-daily Pygeum
A multicenter, randomized, double-blind trial comparing once-daily dosing (100 mg) versus twice-daily dosing (50 mg BID) of Pygeum africanum extract (Tadenan) in 209 men with symptomatic BPH over 60 days. This dose-optimization study established the practicality of once-daily dosing.
Findings: Both dosing regimens (100 mg once daily and 50 mg twice daily) produced equivalent improvements in IPSS, maximum urinary flow rate, post-void residual volume, and quality of life measures. There was no statistically significant difference between the two dosing schedules across any primary or secondary endpoint. Tolerability was excellent and equivalent in both groups. The study established that once-daily dosing of 100 mg is as effective as the previously standard twice-daily regimen, improving compliance.
Limitations: No placebo arm (both groups received active treatment). 60-day duration. Did not evaluate doses below 50 mg/day or above 100 mg/day. Single commercial product.
[7]
Chatelain et al. long-term open-label study of Pygeum for BPH
Open-label study evaluating the long-term efficacy and safety of Pygeum africanum extract (Tadenan, 100 mg/day) in 85 men with symptomatic BPH treated for 12 months, providing the longest continuous treatment data for Pygeum.
Findings: Sustained clinical improvement was observed over the full 12-month treatment period. IPSS decreased progressively from baseline throughout treatment, with the greatest improvement observed between months 2 and 6, followed by continued stable benefit through month 12. Quality of life scores improved significantly. Maximum urinary flow rate improved and was maintained. No evidence of tachyphylaxis (loss of efficacy over time). Adverse events remained mild and infrequent over the 12-month period, with no new safety signals emerging with extended use. Withdrawal rate due to adverse effects was very low.
Limitations: Open-label design without placebo control (susceptible to placebo effect and observer bias). Relatively small sample size (n=85). Single-center. Self-selected population of responders willing to continue treatment for 12 months. Does not address whether benefits persist after treatment discontinuation.
[8]
In vitro mechanisms: anti-proliferative and hormonal effects on prostate cells
Laboratory studies investigating the cellular and molecular mechanisms by which Pygeum bark extract and its isolated constituents affect prostatic cells, providing mechanistic evidence for its clinical effects in BPH.
Findings: Multiple mechanistic pathways have been identified: (1) Beta-sitosterol and the whole extract inhibit 5-alpha-reductase activity in prostatic tissue homogenates, reducing DHT formation; (2) n-Docosyl ferulate inhibits basic fibroblast growth factor (bFGF)-induced proliferation of prostatic fibroblasts -- a key mechanism in stromal hyperplasia; (3) The extract inhibits epidermal growth factor (EGF) receptor binding in prostatic cell lines; (4) Ursolic acid and oleanolic acid suppress NF-kB-mediated transcription of pro-inflammatory genes in prostatic stromal cells; (5) Beta-sitosterol inhibits prostaglandin E2 and F2-alpha synthesis in prostatic tissue via phospholipase A2 and COX-2 inhibition; (6) The extract inhibits aromatase activity, reducing local estrogen production. These combined mechanisms explain the clinical observation that Pygeum improves both obstructive and irritative LUTS by targeting inflammation, edema, and proliferation simultaneously.
Limitations: In vitro studies use isolated cell systems that may not perfectly reflect in vivo conditions. Concentrations of individual compounds tested may differ from those achievable in prostatic tissue after oral dosing. Cell line studies cannot capture the complex prostatic microenvironment. Translation from in vitro to clinical efficacy is not guaranteed.
Edgar & Levin review: Pygeum extract in the treatment of BPH
Comprehensive narrative review synthesizing the phytochemistry, pharmacology, clinical evidence, and practical recommendations for Pygeum africanum bark extract in BPH management. Published in Reviews in Urology.
Findings: Confirmed three distinct pharmacological mechanisms of action: (1) anti-inflammatory via inhibition of 5-lipoxygenase, COX-2, and prostatic PGE2 production (phytosterols and triterpenes); (2) anti-edema via reduction of prostatic vascular permeability and fluid accumulation (triterpenes); (3) anti-proliferative/anti-androgenic via 5-alpha-reductase inhibition and growth factor modulation (ferulic acid esters and phytosterols). The review concluded that Pygeum extract has a level of evidence comparable to other phytotherapies used for BPH (saw palmetto, nettle root, pumpkin seed) and can be recommended as first-line treatment for mild-to-moderate BPH symptoms or as adjunctive therapy to pharmaceutical agents for more severe symptoms.
Limitations: Narrative review without formal systematic methodology. Some cited studies are older and do not use current outcome measurement standards (IPSS was not universally used). Limited direct comparison data with pharmaceutical BPH treatments.
[1]
Beta-sitosterol for BPH (Cochrane systematic review of beta-sitosterol preparations)
While not specific to Pygeum extract, the Cochrane systematic review of beta-sitosterol preparations for BPH (Wilt et al. 1999, updated 2000) is directly relevant because beta-sitosterol is the dominant phytosterol in Pygeum bark extract. This review analyzed preparations of beta-sitosterol from various plant sources for BPH treatment.
Findings: Analyzed 4 RCTs (n=519) of beta-sitosterol preparations for BPH. Beta-sitosterol significantly improved urinary symptom scores (WMD -4.9 IPSS points, 95% CI -6.3 to -3.5), maximum urinary flow rate (WMD +3.91 mL/s), and reduced post-void residual volume (WMD -28.6 mL) compared to placebo. The improvements were clinically meaningful and statistically robust. This provides supporting evidence that the phytosterol content of Pygeum bark extract is a major contributor to its clinical efficacy.
Limitations: Not specific to P. africana -- beta-sitosterol preparations from various plant sources were studied. Different beta-sitosterol doses and formulations across studies. Limited long-term data. Does not address the contribution of other Pygeum constituents (triterpenes, ferulic acid esters).
[10]
Preparations & Dosage
Standardized Extract
Strength: Standardized lipophilic extract: 14% triterpenes (ursolic acid + oleanolic acid), 0.5% n-docosanol. Drug-extract ratio approximately 200:1 (200 kg bark yields approximately 1 kg extract).
The standardized lipophilic bark extract is the form used in essentially all clinical trials and is the recommended preparation for therapeutic use. The extract is produced by n-hexane or chloroform-methanol extraction of dried bark, yielding a lipophilic fraction concentrated in phytosterols, triterpenes, and ferulic acid esters. The reference product is Tadenan (also designated V1326), manufactured initially by Laboratoires Fournier (France). The extract is standardized to contain approximately 14% pentacyclic triterpenes (as ursolic acid + oleanolic acid) and 0.5% n-docosanol (as docosyl ferulate). Available commercially as soft gelatin capsules, typically 50 mg or 100 mg per capsule.
100 mg per day of standardized extract (either 100 mg once daily or 50 mg twice daily -- both regimens shown equally effective in the Yablonsky et al. 1997 trial). This is the dose used in the majority of positive clinical trials and recommended by the Cochrane review.
Once daily (100 mg) or twice daily (50 mg). Once-daily dosing is preferred for compliance.
Minimum 6-8 weeks for initial assessment of efficacy. Clinical trials ranged from 4 weeks to 12 months. Sustained benefit demonstrated with continuous use up to 12 months (Chatelain et al. 1999). Can be used long-term as symptoms persist. Reassess periodically.
Not applicable. BPH is not a pediatric condition. No pediatric indications for Pygeum have been studied.
The standardized extract is the ONLY form with robust clinical trial evidence for efficacy in BPH. Crude bark preparations (decoctions, powders) have traditional use in Africa but have not been studied in controlled clinical trials at the same level. The extremely high drug-extract ratio (200:1) means that very large amounts of crude bark would be needed to approximate the doses used in clinical trials. This makes standardized extract the only practical therapeutic form for clinical BPH treatment. Product quality varies; consumers should verify standardization parameters (% triterpenes, % n-docosanol) and look for products manufactured to European GMP standards. The French Pharmacopoeia includes a monograph on the standardized Prunus africana bark extract.
Capsule / Powder
Strength: Crude dried bark powder, typically 500 mg per capsule
Dried bark, finely powdered and encapsulated. This is a less concentrated form than the standardized extract and is used primarily in dietary supplements in the US market where standardized extract products may be less available or more expensive. Powdered bark capsules contain the full spectrum of bark constituents including tannins, which are absent from the lipophilic standardized extract.
500-1000 mg of powdered bark, 2-3 times daily. Total daily dose: 1000-3000 mg. Note: this is NOT equivalent to 100 mg of standardized extract due to the approximately 200:1 extraction ratio.
Two to three times daily with meals
Minimum 6-8 weeks. May require longer treatment than standardized extract due to lower concentration of active constituents.
Not applicable
Crude bark powder capsules are more widely available in the US supplement market than the European standardized extract (Tadenan). However, the clinical evidence base is built almost entirely on the standardized extract, and crude powder has not been validated in clinical trials to the same degree. The effective dose of active constituents in crude powder is substantially lower per capsule than in standardized extract. Some US manufacturers offer bark powder capsules with some degree of standardization (e.g., standardized to phytosterol content), which may bridge the gap between crude powder and full standardized extract.
Tincture
Strength: 1:5 in 45-60% ethanol (dried bark). Some practitioners use 1:3 in 60% ethanol for a stronger preparation.
Dried bark, finely chopped or coarsely powdered, macerated in 45-60% ethanol (higher alcohol percentage improves extraction of lipophilic phytosterols and triterpenes from the dense bark material). Standard maceration: 1:5 ratio, steep for 4-6 weeks with daily shaking. Press and filter. A higher-strength tincture (1:3 in 60% ethanol) may improve extraction of lipophilic constituents.
3-5 mL (60-100 drops) three times daily
Three times daily
Minimum 6-8 weeks for initial assessment. May be used long-term.
Not applicable
Tincture preparation allows extraction of both water-soluble (tannins, some phenolics) and ethanol-soluble (phytosterols, triterpenes, ferulic acid esters) constituents, providing a broader chemical profile than either aqueous decoction or lipophilic extract alone. However, the concentration of key active constituents (beta-sitosterol, triterpenes, docosyl ferulate) achievable in a tincture is far lower than in the standardized extract. Tincture may be appropriate for mild symptoms, as part of a multi-herb BPH formula, or as a maintenance preparation. It has not been validated in clinical trials.
[1]
Decoction
Strength: 15-25 g dried bark per 500-750 mL water (approximately 1:30-1:50)
The traditional African preparation method. Add 15-25 g of dried bark (or 30-50 g of fresh bark) to 500-750 mL of cold water. Bring to a boil, then reduce to a steady simmer for 20-30 minutes. The bark is dense and requires sustained heat to extract constituents. Strain and drink while still warm. The decoction will be dark reddish-brown with a pronounced bitter and astringent taste.
150-250 mL (one teacup) of decoction, 2-3 times daily
Two to three times daily
Continuous use for weeks to months in traditional practice
Not applicable for prostate indications
The decoction is the traditional African preparation and extracts primarily water-soluble constituents: tannins, water-soluble phenolics, and some phytosterols. The lipophilic active constituents (phytosterols, triterpenes, ferulic acid esters) are only partially extracted by water, meaning that the decoction provides a different pharmacological profile than the standardized lipophilic extract used in clinical trials. The decoction has the advantage of extracting the tannin fraction, which provides astringent and tissue-toning properties valued in traditional practice. This preparation has not been studied in controlled clinical trials.
Safety & Interactions
Class 1
Can be safely consumed when used appropriately (AHPA Botanical Safety Handbook)
Contraindications
Although allergic reactions to Pygeum bark extract are extremely rare in the clinical literature (no serious allergic events reported across 18 RCTs in the Cochrane review), individuals with confirmed allergy to the bark or to closely related Rosaceae species should avoid use. Cross-reactivity with other Prunus species allergens is theoretically possible.
Drug Interactions
| Drug / Class | Severity | Mechanism |
|---|---|---|
| Finasteride, dutasteride (5-alpha-reductase inhibitors) (5-alpha-reductase inhibitors) | theoretical | Pygeum extract contains constituents (beta-sitosterol, n-docosyl ferulate) that inhibit 5-alpha-reductase at the prostatic tissue level. Concurrent use with pharmaceutical 5-alpha-reductase inhibitors could theoretically produce additive anti-androgenic effects in the prostate. However, this interaction may actually be beneficial (enhanced efficacy) rather than harmful. |
| Tamsulosin, terazosin, doxazosin (alpha-1-adrenergic blockers) (Alpha-adrenergic blockers) | theoretical | Alpha-blockers relax prostatic and bladder neck smooth muscle to relieve urinary obstruction. Pygeum addresses BPH symptoms through different mechanisms (anti-inflammatory, anti-edema, anti-proliferative). The two approaches are mechanistically complementary rather than interacting adversely. |
| Serenoa repens (saw palmetto) extract (Herbal BPH preparations) | minor | Both herbs target BPH symptoms through overlapping but not identical mechanisms. Saw palmetto (Serenoa repens) is also a 5-alpha-reductase inhibitor with anti-inflammatory and anti-androgenic effects in the prostate. Combination may produce additive or synergistic benefit. |
Pregnancy & Lactation
Pregnancy
insufficient data
Lactation
insufficient data
Pygeum bark extract is used almost exclusively in men for BPH and prostate conditions, so pregnancy and lactation are not clinically relevant considerations for its primary indication. No safety studies in pregnant or breastfeeding women have been conducted. The anti-androgenic and hormonal-modulating properties of the extract raise theoretical concerns for fetal development if used during pregnancy. There is no clinical reason for a pregnant or lactating woman to use Pygeum bark extract.
Adverse Effects
References
Monograph Sources
- [1] Edgar AD, Levin R, Constantinou CE, Denis L. A critical review of the pharmacology of the plant extract of Pygeum africanum in the treatment of LUTS. Neurourol Urodyn (2007) ; 26 : 458-463 . DOI: 10.1002/nau.20136 . PMID: 17192049
- [2] Cunningham AB. African Medicinal Plants: Setting Priorities at the Interface Between Conservation and Primary Healthcare. People and Plants Working Paper 1, UNESCO, Paris (1993)
- [3] Stewart KM. The African cherry (Prunus africana): Can lessons be learned from an over-exploited medicinal tree?. J Ethnopharmacol (2003) ; 89 : 3-13 . DOI: 10.1016/j.jep.2003.08.002 . PMID: 14522426
Clinical Studies
- [4] Ishani A, MacDonald R, Nelson D, Rutks I, Wilt TJ. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis. Am J Med (2000) ; 109 : 654-664 . DOI: 10.1016/S0002-9343(00)00604-5 . PMID: 11099686
- [5] Breza J, Dzurny O, Borowka A, Hanus T, Petrik R, Blane G, Chadha-Boreham H. Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): a multicentre trial in central Europe. Curr Med Res Opin (1998) ; 14 : 127-139 . DOI: 10.1185/03007999809113352 . PMID: 9787978
- [6] Barlet A, Albrecht J, Aubert A, Fischer M, Grof F, Grothuesmann HG, Masson JC, Mazeman E, Merber R, Moulonguet A, Richou H, Steiner R. Efficacy of Pygeum africanum extract in the medical therapy of urination disorders due to benign prostatic hyperplasia: evaluation of objective and subjective parameters. A placebo-controlled double-blind multicenter study. Wien Klin Wochenschr (1990) ; 102 : 667-673 . PMID: 1702917
- [7] Yablonsky F, Nicolas V, Riffaud JP, Bellamy F. Antiproliferative effect of Pygeum africanum extract on rat prostatic fibroblasts. J Urol (1997) ; 157 : 2381-2387 . DOI: 10.1016/S0022-5347(01)64781-6 . PMID: 9146672
- [8] Chatelain C, Autet W, Brackman F. Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension. Urology (1999) ; 54 : 473-478 . DOI: 10.1016/S0090-4295(99)00180-0 . PMID: 10475357
- [9] Andro MC, Riffaud JP. Pygeum africanum extract for the treatment of patients with benign prostatic hyperplasia: a review of 25 years of published experience. Curr Ther Res (1995) ; 56 : 796-817 . DOI: 10.1016/0011-393X(95)85063-5
- [10] Wilt TJ, MacDonald R, Ishani A. Beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review. BJU Int (1999) ; 83 : 976-983 . DOI: 10.1046/j.1464-410x.1999.00026.x . PMID: 10368239
Traditional Texts
- [11] Neuwinger HD. African Traditional Medicine: A Dictionary of Plant Use and Applications. Medpharm Scientific Publishers, Stuttgart (2000) . ISBN: 978-3887630867
Pharmacopeias & Reviews
- [12] Agence Nationale de Securite du Medicament et des produits de sante (ANSM). Pharmacopee Francaise: Monographie Prunier d'Afrique (ecorce de). Pharmacopee Francaise, 12th edition (2021)
- [13] World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4: Cortex Pruni africanae. World Health Organization, Geneva (2009) . ISBN: 978-9241547055
- [14] European Scientific Cooperative on Phytotherapy (ESCOP). ESCOP Monographs: Pygei africani cortex (Pygeum bark). ESCOP Monographs, 2nd edition. Thieme, Stuttgart (2003) . ISBN: 978-1588900067
Last updated: 2026-03-02 | Status: review
Unlock the Full Materia Medica
This monograph is part of our complete evidence-based herbal reference. Enter your email to get free, unlimited access to all of our monographs.
No spam, ever. Unsubscribe anytime.
You're In!
You now have full access to all of our herbal monographs.